Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Consultation of Draft Guidance Documents: Identifying and Labelling Medicinal Ingredients, Generic Drug Equivalence: Medicinal Ingredients - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 256444
Later capture
Consultation of Draft Guidance Documents: Identifying and Labelling Medicinal Ingredients, Generic Drug Equivalence: Medicinal Ingredients - Canada.ca
Jan 2, 2026
hc-20260101
ID 428632
updated2 sections changed
2 sections changed0 added0 removed+0 / -3 linesChange ratio: 4%
--- +++ @@ -1,6 +1,4 @@ Consultation of Draft Guidance Documents: Identifying and Labelling Medicinal Ingredients, Generic Drug Equivalence: Medicinal Ingredients-From:-Health Canada Current status: Closed This consultation ran from April 8, 2019 to June 17, 2019. Health Canada is proposing amendments to the Food and Drug Regulations that would provide greater clarity to the pharmaceutical industry on criteria for which regulatory pathway to follow when filing generic drug submissions to Health Canada and, requirements for labelling for new drug products. The draft guidance documents Identifying and Labelling Medicinal Ingredients and Generic Drug Equivalence: Medicinal Ingredients outline the implementation of the regulatory proposal that was consulted on in Canada Gazette I.@@ -35,5 +33,4 @@ Email: hc.policy.bureau.enquiries.sc@canada.ca Page details-Date modified: 2021-07-23